CEO Zook exits Vivus, J&J's Fischer steps in
This article was originally published in Scrip
Vivus' freshly appointed CEO, Tony Zook who joined the Mountain View, California-based firm from big pharma AstraZeneca, has stepped down due to "a previously-diagnosed medical condition." Taking up the position instead is Seth H Z Fischer, former Johnson and Johnson company group, and worldwide franchise chair – effective 3 September 2013. Mr Fischer will also join the Vivus board of directors.
You may also be interested in...
Orexigen hoped its go-it-alone strategy would boost obesity drug Contrave's sales enough to keep the company afloat, but now it has initiated bankruptcy proceedings, following through on a warning in October that it might not meet debt holders' requirements.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.